High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: A clinicopathological, immunohistochemical and mutational study of 20 cases

Histopathology

Volumn 67, Issue 6, 2015, Pages 806-816

  Suzuki, Masaki ^a,b   Yazawa, Takuya ^a   Ota, Satoshi ^b   Morimoto, Junichi ^a   Yoshino, Ichiro ^a   Yamanaka, Shoji ^c   Inayama, Yoshiaki ^d   Kawabata, Yoshinori ^e   Shimizu, Yoshihiko ^e   Komatsu, Masayo ^f   Notohara, Kenji ^g   Koda, Kenji ^h   Nakatani, Yukio ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e Saitama Cardiovascular and Respiratory Centre ^*  (Japan)

^f Yamamoto Kumiai General Hospital   (Japan)

^g Kurashiki Chuo Hospital   (Japan)

^h FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

Author keywords

Fetal adenocarcinoma; Genetic analysis; Neuroendocrine carcinoma; fetoprotein; catenin

Indexed keywords

ALPHA FETOPROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHORIOCARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENTERIC ADENOCARCINOMA; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HIGH GRADE FETAL LUNG ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; SMOKING; TUMOR DIFFERENTIATION; VERY ELDERLY; ADENOCARCINOMA; CANCER GRADING; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG; LUNG TUMOR; METABOLISM; MUTATION; NEUROENDOCRINE TUMOR; PATHOLOGY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 84955211488     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12711     Document Type: Article

References (46)

1. Kradin RL, Young RH, Dickersin GR, Kirkham SE, Mark EJ. Pulmonary blastoma with argyrophil cells and lacking sarcomatous features (pulmonary endodermal tumor resembling fetal lung). Am. J. Surg. Pathol. 1982; 6; 165-172.
2. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J. Thorac. Oncol. 2011; 6; 244-285.
3. Nakatani Y, Kitamura H, Inayama Y et al. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am. J. Surg. Pathol. 1998; 22; 399-411.
4. Koss MN, Hochholzer L, O'Leary T. Pulmonary blastomas. Cancer 1991; 67; 2368-2381.
5. Sato S, Koike T, Yamato Y, Yoshiya K, Honma K, Tsukada H. Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases reported in Japan. Jpn. J. Thorac. Cardiovasc. Surg. 2006; 54; 539-542.
6. Morita S, Yoshida A, Goto A et al. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. Am. J. Surg. Pathol. 2013; 37; 924-932.
7. Nakatani Y, Masudo K, Miyagi Y et al. Aberrant nuclear localisation and gene mutation of β-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod. Pathol. 2002; 15; 617-624.
8. Li J, Bai X, Zou Y, Hao Y, Xu X. Aberration of the Wnt signaling pathway in pulmonary fatal adenocarcinoma: a case report. Chin. J. Cancer Res. 2014; 26; E13-E16.
9. Sekine S, Shibata T, Matsuno Y et al. β-Catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol. 2003; 200; 214-221.
10. Proctor L, Folpe AL, Esper A, Wolfenden LL, Force S, Logani S. Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fine-needle aspiration with emphasis on use of β-catenin as a useful diagnostic marker. Diagn. Cytopathol. 2007; 35; 39-42.
11. Ball DW, Azzoli CG, Baylin SB et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc. Natl Acad. Sci. USA 1993; 90; 5648-5652.
12. Ishii J, Sato H, Sakaeda M et al. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer. Pathol. Int. 2013; 63; 158-168.
13. Hiroshima K, Iyoda A, Shida T et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod. Pathol. 2006; 19; 1358-1368.
14. Jiang SX, Kameya T, Asamura H et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod. Pathol. 2004; 17; 222-229.
15. Kashiwagi K, Ishii J, Sakaeda M et al. Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells. Pathol. Int. 2012; 62; 232-245.
16. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
17. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005; 6; 279-286.
18. Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA. BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle 2009; 8; 1402-1408.
19. Palomba G, Colombino M, Contu A et al. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J. Transl. Med. 2012; 10; 178-186.
20. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48; 452-458.
21. Segawa Y, Takata S, Fujii M et al. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J. Cancer Res. Clin. Oncol. 2009; 135; 1055-1059.
22. Ionescu DN, Treaba D, Gilks CB et al. Non-small cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am. J. Surg. Pathol. 2007; 31; 26-32.
23. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005; 46; 195-201.
24. Matsuki Y, Tanimoto A, Hamada T, Sasaguri Y. Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. Mod. Pathol. 2003; 16; 72-78.
25. Sakaeda M, Sato H, Ishii J et al. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer. Lab. Invest. 2013; 93; 408-421.
26. Kosari F, Ida CM, Aubry MC et al. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene 2014; 33; 3776-3783.
27. Morrisey EE, Hogan BL. Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev. Cell 2010; 18; 8-23.
28. Nakatani Y. Pulmonary endocrine cells in infancy and childhood. Pediatr. Pathol. 1991; 11; 31-48.
29. Volante M, Fulcheri E, Allia E, Cerrato M, Pucci A, Papotti M. Ghrelin expression in fetal, infant, and adult human lung. J. Histochem. Cytochem. 2002; 50; 1013-1021.
30. Nakatani Y, Miyagi Y, Takemura T et al. Aberrant nuclear/cytoplasmic localisation and gene mutation of β-catenin in classic pulmonary blastoma: β-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am. J. Surg. Pathol. 2004; 28; 921-927.
31. Suzuki M, Ota S, Inayama Y et al. Blastomatoid carcinosarcoma of the lung is a biphasic tumor of high-grade that needs to be distinguished from pulmonary blastoma: a clinicopathological and immunohistochemical analysis of 13 cases. Mod. Pathol. 2014; 27; 496A.
32. Nakatani Y, Hiroshima K. Fetal adenocarcinoma. Pathol. Clin. Med. 2010; 28; 252-258.
33. Flieder DB, Borczuk AC, Noguchi M. Adenocarcinoma of the lung. In Hasleton P, Fliede DB eds. Spencer's pathology of the lung. 6th ed. Cambridge: Cambridge University Press, 2013; 1043-1092.
34. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am. J. Clin. Pathol. 2001; 115; 689-694.
35. Kodama T, Kameya T, Hirota T et al. Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: histologic and immunohistochemical analyses of 35 cases. Cancer 1981; 48; 1647-1655.
36. Ushiku T, Uozaki H, Shinozaki A et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and α-fetoprotein-producing gastric carcinomas. Cancer Sci. 2009; 100; 626-632.
37. Matsunou H, Konishi F, Jalal RE, Yamamichi N, Mukawa A. Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer 1994; 73; 534-540.
38. Ushiku T, Shinozaki A, Shibahara J et al. Sall4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am. J. Surg. Pathol. 2010; 34; 533-540.
39. Hishinuma M, Ohashi KI, Yamauchi N et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for α-fetoprotein-producing gastric carcinoma. Histopathology 2006; 49; 479-486.
40. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J. Thorac. Oncol. 2009; 4; 22-29.
41. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005; 23; 2513-2520.
42. Haneda H, Sasaki H, Lindeman N et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn. J. Clin. Oncol. 2006; 36; 69-75.
43. Broet P, Dalmasso C, Tan EH et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin. Cancer Res. 2011; 17; 3542-3550.
44. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med. Oncol. 2013; 30; 645-648.
45. Yousem SA. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung. Hum. Pathol. 2013; 44; 2467-2474.
46. Kinno T, Tsuta K, Shiraishi K et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann. Oncol. 2014; 25; 138-142.